On May 10, 2006, the regulator of assisted reproduction in theUnited Kingdom the Human Fertilisation and EmbryologyAuthority (HFEA) decided to include susceptibilitiesto certain cancers in the conditions for which it will allowpreimplantation genetic diagnosis (PGD).1 In Britain, as inmost of Europe, PGD refers to the removal of a single cell froman embryo generated in vitro for genetic testing to diagnosea recurrent, serious, heritable condition and thereby to avoidthe implantation of affected embryos (see diagram). The techniqueis used by fertile couples, as an alternative to prenatal diagnosiswith the . . . [Full Text of this Article]
Source Information
Prof. Braude is the head of the Department of Women's Health at King's College London, School of Medicine, London.
Amor, D. J., Cameron, C.
(2008). PGD gender selection for non-Mendelian disorders with unequal sex incidence. Hum Reprod
23: 729-734
[Abstract][Full Text]
Braude, P., Flinter, F.
(2007). Use and misuse of preimplantation genetic testing. BMJ
335: 752-754
[Full Text]
Offit, K., Sagi, M., Hurley, K.
(2006). Preimplantation Genetic Diagnosis for Cancer Syndromes: A New Challenge for Preventive Medicine. JAMA
296: 2727-2730
[Full Text]
Gibbons, W. E.
(2006). Preimplantation Diagnosis for Genetic Susceptibility. NEJM
355: 2048-2048
[Full Text]